Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stake Boosted by Freedom Day Solutions LLC

Freedom Day Solutions LLC raised its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 0.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,449 shares of the biopharmaceutical company’s stock after purchasing an additional 19 shares during the period. Freedom Day Solutions LLC’s holdings in Regeneron Pharmaceuticals were worth $2,574,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of REGN. Stephens Consulting LLC bought a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter valued at about $26,000. Sachetta LLC grew its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth approximately $28,000. Lynx Investment Advisory bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. Finally, Family Firm Inc. bought a new stake in shares of Regeneron Pharmaceuticals in the 2nd quarter worth approximately $33,000. 83.31% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, VP Jason Pitofsky sold 487 shares of the stock in a transaction that occurred on Wednesday, August 7th. The stock was sold at an average price of $1,070.00, for a total value of $521,090.00. Following the transaction, the vice president now owns 4,204 shares in the company, valued at approximately $4,498,280. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.48% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on REGN shares. Leerink Partnrs lowered Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. JPMorgan Chase & Co. decreased their price objective on Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday. Canaccord Genuity Group reaffirmed a “buy” rating and set a $1,152.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Wells Fargo & Company decreased their price target on Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating for the company in a research note on Tuesday. Finally, Piper Sandler raised their price target on Regeneron Pharmaceuticals from $1,166.00 to $1,242.00 and gave the company an “overweight” rating in a report on Friday, August 23rd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $1,101.00.

Regeneron Pharmaceuticals Trading Down 1.3 %

NASDAQ:REGN opened at $928.90 on Friday. The stock has a market cap of $102.40 billion, a PE ratio of 24.60, a price-to-earnings-growth ratio of 3.29 and a beta of 0.12. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $769.19 and a fifty-two week high of $1,211.20. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.44 and a quick ratio of 4.62. The stock’s 50-day moving average is $1,098.29 and its two-hundred day moving average is $1,040.67.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 EPS for the quarter, beating analysts’ consensus estimates of $8.93 by $2.63. The firm had revenue of $3.55 billion for the quarter, compared to the consensus estimate of $3.38 billion. Regeneron Pharmaceuticals had a net margin of 32.04% and a return on equity of 16.80%. The firm’s revenue was up 12.3% on a year-over-year basis. During the same period in the previous year, the firm posted $8.79 earnings per share. As a group, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 37.66 earnings per share for the current fiscal year.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.